Search results for ''
ENYO Pharma SA announces successful initiation of the Phase 1 clinical programme with EYP001, its lead candidate for the treatment of Chronic Hepatitis B Virus infection.
Lyon, December 16, 2016 – ENYO Pharma SA, a privately held biopharmaceutical company currently focused on developing treatments for viral infections, today announced that the Phase 1 single and multiple ascending dose trial evaluating EYP001 in healthy subjects has been initiated, and that single dose escalation has been completed. The results have shown that EYP001 is safe and well-tolerated at all doses studied in 46 healthy subjects. The safety and pharmacokinetics (PK) analysis of these first Phase 1 data will be complete by Q2 2017.
ENYO Pharma receives Tranche 2 of its Series A investment.
ENYO Pharma has received the 10 M€ Tranche 2 of its Series A investment. The Board of Directors unanimously requested the Investors release this second Tranche of the 22 M€ Series A which closed in January 2016. This release is a response to several successfully achieved milestones, most importantly the Board decision to initiate Phase 1b in chronically infected, HBV patients. The first patients enrolment is planned for Q2 2017.
ENYO Pharma receives a €2.5 million grant from EU under the Horizon2020/SME Instrument Phase 2 programme for its project MIMESIS
Lyon, December 5, 2016 – ENYO Pharma, a biopharmaceutical company currently focused on developing treatments for viral infections, today announced that it has received a grant of €2.5 million in response to its application to the highly competitive SME Instrument Phase 2 funding programme (6% success rate).
ENYO Pharma strengthens its management team to support its strategy of international growth
Lyon, November 7, 2016 – ENYO Pharma strengthens its management team to support its strategy of international growth.
J.P. Morgan 35th Annual Healthcare Conference
January 09-13, 2017
San Francisco, CA, USA
Jacky Vonderscher will be at San Francisco during the J.P. Morgan conference.
Latest Press Release 